In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 141-30-0, name is 3,6-Dichloropyridazine, introducing its new discovery. Quality Control of 3,6-Dichloropyridazine
This Letter reports the synthesis and biological evaluation of a collection of aminophthalazines as a novel class of compounds capable of reducing production of PGE2 in HCA-7 human adenocarcinoma cells. A total of 28 analogs were synthesized, assayed for PGE2 reduction, and selected active compounds were evaluated for inhibitory activity against COX-2 in a cell free assay. Compound 2xxiv (R1 = H, R2 = p-CH 3O) exhibited the most potent activity in cells (EC50 = 0.02 muM) and minimal inhibition of COX-2 activity (3% at 5 muM). Furthermore, the anti-tumor activity of analog 2vii was analyzed in xenograft mouse models exhibiting good anti-cancer activity.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 141-30-0, and how the biochemistry of the body works.Quality Control of 3,6-Dichloropyridazine
Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N1820 – PubChem